User profiles for Srinivasa P.S. Rao
Srinivasa PS RaoNovartis Institute for Tropical Diseases Verified email at novartis.com Cited by 6024 |
[HTML][HTML] New drugs for human African trypanosomiasis: a twenty first century success story
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging
across many parts of Africa. Resistance to existing drugs was emerging, and many programs …
across many parts of Africa. Resistance to existing drugs was emerging, and many programs …
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis
The persistence of Mycobacterium tuberculosis despite prolonged chemotherapy represents
a major obstacle for the control of tuberculosis. The mechanisms used by Mtb to persist in a …
a major obstacle for the control of tuberculosis. The mechanisms used by Mtb to persist in a …
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread
of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease, …
of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease, …
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
…, A Brock, JC Mottram, FS Buckner, SPS Rao… - Nature, 2016 - nature.com
Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide
and lead to more than 50,000 deaths annually 1 . The diseases are caused by infection with …
and lead to more than 50,000 deaths annually 1 . The diseases are caused by infection with …
Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and …
The ability of Mycobacterium tuberculosis to persist in its human host despite extensive
chemotherapy is thought to be based on subpopulations of non-replicating phenotypically drug-…
chemotherapy is thought to be based on subpopulations of non-replicating phenotypically drug-…
[HTML][HTML] A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy
…, A Chatterjee, MP Tan, M Ujjini, SPS Rao… - Nature …, 2010 - nature.com
Candidate antibacterials are usually identified on the basis of their in vitro activity. However,
the apparent inhibitory activity of new leads can be misleading because most culture media …
the apparent inhibitory activity of new leads can be misleading because most culture media …
[HTML][HTML] Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science
SPS Rao, UH Manjunatha, S Mikolajczak… - Trends in …, 2023 - cell.com
While prevention is a bedrock of public health, innovative therapeutics are needed to
complement the armamentarium of interventions required to achieve disease control and …
complement the armamentarium of interventions required to achieve disease control and …
The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease
…, P Krastel, C Noble, D Beer, SPS Rao… - Angewandte Chemie …, 2011 - infona.pl
Target practice: The target of the antibiotic cyclomarin A was identified in Mycobacterium.
Cyclomarin A (see structure) binds the regulatory subunit of the Clp protease complex with …
Cyclomarin A (see structure) binds the regulatory subunit of the Clp protease complex with …
Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis
SPS Rao, SB Lakshminarayana… - Science translational …, 2013 - science.org
New chemotherapeutic compounds against multidrug-resistant Mycobacterium tuberculosis
(Mtb) are urgently needed to combat drug resistance in tuberculosis (TB). We have identified …
(Mtb) are urgently needed to combat drug resistance in tuberculosis (TB). We have identified …
Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
… Srinivasa PS Rao Srinivasa PS Rao … Manjunatha, Véronique Dartois, Thomas Dick, Srinivasa
PS Rao, Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB …
PS Rao, Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB …